Semax (ACTH Fragment Peptide)

What the Melanocortin Neuroprotection Literature Reports

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

A body of work has examined melanocortin peptides in models of neural injury. Catania reviewed neuroprotective actions of melanocortins in Trends in Neurosciences in 2008, and Giuliani and colleagues examined MC4R-stimulating melanocortins in cerebral ischaemia models in Endocrinology in 2006.

Key facts

Catania 2008
Trends Neurosci review (PMID 18550183)
Giuliani 2006
Endocrinology (PMID 16254026)
Receptor implicated
MC4R
Model
Cerebral ischaemia, in animals
Notable design feature
Early and delayed treatment compared
Human evidence
Not established

Why melanocortins were examined in the brain at all

Melanocortin receptors are not confined to skin and adrenal tissue. MC3R and MC4R are expressed centrally, which is why the same receptor family that governs pigmentation also participates in energy balance. Central expression makes neural effects a coherent hypothesis rather than a stretch.

What the 2006 work examined

Giuliani and colleagues compared both early and delayed treatment with MC4R-stimulating melanocortins in cerebral ischaemia. Testing delayed as well as early administration is the more demanding design. An intervention that only works if given before or immediately at injury has limited relevance, since real injuries are not anticipated.

Research material referenced

Semax 10mg, third-party HPLC tested

Buy Semax · £24.99

Why the delayed arm is the informative one

Many interventions protect tissue in animal ischaemia models when given prophylactically. Very few retain effect when administration is delayed, and that gap is a major reason neuroprotection findings have translated poorly from animals to humans. A study reporting both is testing the harder and more relevant question.

What the review contributed

Catania described neuroprotective actions of melanocortins as a therapeutic opportunity in Trends in Neurosciences in 2008. A review in a journal of that kind indicates the field considered the finding worth surveying, and the word opportunity conveys the stage accurately, then and arguably now.

Why this connects to Semax without transferring to it

Semax derives from the same precursor region, so this literature is context for the family. But Semax replaces positions 8 to 10 with Pro-Gly-Pro, and those replaced residues are part of the melanocortin receptor-binding core that MT-2 is built around. A compound that discards the receptor core is not straightforwardly described by findings about receptor-stimulating melanocortins.

What is not being claimed

Anything about neuroprotection in any person. This is animal model literature and a review of it, reported as what was measured and in what model. Semax holds no marketing authorisation from the MHRA, EMA or FDA and is supplied here for laboratory research only.

Frequently asked questions

Are melanocortin receptors present in the brain?

Yes. MC3R and MC4R are expressed centrally, which is why the same family that governs pigmentation also participates in energy balance.

Why does delayed treatment matter?

Many interventions protect in animal ischaemia models when given prophylactically; few retain effect when delayed, and real injuries are not anticipated.

Does this literature apply to Semax?

Only as family context. Semax replaces positions 8 to 10, which are part of the receptor-binding core these studies concern.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Semax (ACTH Fragment Peptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.